Percutaneous coronary intervention by using drug-eluting stents (DESs) has become increasingly popular as standard therapy for the patients with acute coronary syndrome. At this point in time, 12 months of dual antiplatelet therapy (DAT), asprin and clopidogrel, is recommended for all patients who receive a DES unless there is a high risk of bleeding (1). Concerning bleeding risks, because these antiplatelet agents have recognizable gastroduodenal injury (2, 3), concomitant use of proton pump inhibitors (PPIs) is recommended for all patients with DAT as a guideline (4).
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